Our top pick for
Aemetis Inc is an oil & gas refining & marketing business based in the US. Aemetis shares (AMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Aemetis employs 164 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$19.96|
|52-week range||$1.96 - $27.44|
|50-day moving average||$16.62|
|200-day moving average||$13.79|
|Wall St. target price||$30.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||N/A|
|1 month (2021-09-24)||35.78%|
|3 months (2021-07-26)||101.41%|
|6 months (2021-04-26)||6.34%|
|1 year (2020-10-23)||396.52%|
|2 years (2019-10-25)||1,925.57%|
|3 years (2018-10-25)||2,168.18%|
|5 years (2016-10-25)||1,088.10%|
Valuing Aemetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aemetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aemetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.4 million.
The EBITDA is a measure of a Aemetis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$175.9 million|
|Gross profit TTM||$11 million|
|Return on assets TTM||-10.7%|
|Return on equity TTM||0%|
|Market capitalisation||$632.5 million|
TTM: trailing 12 months
There are currently 3.9 million Aemetis shares held short by investors – that's known as Aemetis's "short interest". This figure is 0.9% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting Aemetis shares can be evaluated.
Aemetis's "short interest ratio" (SIR) is the quantity of Aemetis shares currently shorted divided by the average quantity of Aemetis shares traded daily (recently around 1.2 million). Aemetis's SIR currently stands at 3.35. In other words for every 100,000 Aemetis shares traded daily on the market, roughly 3350 shares are currently held short.
However Aemetis's short interest can also be evaluated against the total number of Aemetis shares, or, against the total number of tradable Aemetis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aemetis's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Aemetis shares in existence, roughly 120 shares are currently held short) or 0.1374% of the tradable shares (for every 100,000 tradable Aemetis shares, roughly 137 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aemetis.
Find out more about how you can short Aemetis stock.
We're not expecting Aemetis to pay a dividend over the next 12 months.
Aemetis's shares were split on a 4:1 basis on 14 June 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Aemetis shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Aemetis shares which in turn could have impacted Aemetis's share price.
Over the last 12 months, Aemetis's shares have ranged in value from as little as $1.96 up to $27.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aemetis's is -0.4735. This would suggest that Aemetis's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aemetis has bucked the trend.
Aemetis, Inc. operates as a renewable natural gas and fuels, and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products. It owns and operates an ethanol facility in the California Central Valley near Modesto; and a renewable chemical and advanced fuel production facility on the East Coast of India. The company sells biodiesel and refined glycerin to transport companies, resellers, distributors, and refiners through its sales force and independent sales agents, as well as to brokers who resell the product to end-users. It also produces and sells ethanol; and wet distiller's grains, distiller's corn oil, and condensed distillers solubles to dairies and feedlots as animal feed, as well as other health care and sanitary products, and industrial and potable alcohol for beverage spirits. In addition, it produces dairy biogas; and high-grade sanitizer alcohol and various feed products, as well as researches and develops efficient conversion technologies using waste feedstocks to produce biofuels and biochemicals.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.